changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
An open-label, prospective, multicenter, randomized, Phase III clinical trial evaluating yttrium-90 transarterial radioembolization with TheraSphere® in patients with metastatic colorectal carcinoma (mCRC) of the liver who have failed first-line chemotherapy.25,26
TheraSphere® plus standard-of-care chemotherapy: oxaliplatin- or irinotecan-based
Standard-of-care chemotherapy: oxaliplatin- or irinotecan-based
To evaluate the efficacy and safety of TheraSphere® in patients with mCRC of the liver scheduled to receive second-line chemotherapy.
Primary: Progression-free survival (per RECIST v1.1)
Secondary: Safety, Overall survival, tumor response, time to symptomatic progression, hepatic progression-free survival, quality of life
Please visit the THERASPHERE TRIALS WEBSITE for more details
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com